For those treated with givosiran, there was a 77% mean reduction in IV heme use and sustained lowering of urinary ALA (86%) and PBG (91%) levels from baseline, greater reductions in daily worst pain, lower analgesic use, and improved quality of life 9,10 compared with those receiving the placebo
Disclosures: Parissa Tabrizian: AstraZeneca: Speaking and Teaching, Aztrazeneca: Speaking and Teaching, Boston Scientific: Speaking and Teaching, Matthew Holzner: Nothing to Disclose, Edison Xu: Nothing to Disclose, Maarouf Hoteit: HepQuant, LLC: Advisor, Veeral Ajmera: Nothing to Disclose, Tara Ghaziani: Nothing to Disclose, Neehar Parikh: Genentech: Grant/Research Support, Exelixis: Grant/Research Support, Exelixis: Consultant, AstraZeneca: Consultant, Exact Sciences: Grant/Research Support, Exact Sciences: Consultant, Fujifilm Medical: Advisor, Kali Zhou: Gilead Sciences Inc: Grant/Research Support, Amy Kim: Nothing to Disclose, Rebecca Marino: Nothing to Disclose, Francis Yao: Nothing to Disclose, Sander Florman: Nothing to Disclose, Neil Mehta: Merck: Consultant, FujiFilm WAKO: Consultant 444 TARGETING THE LIVER CLOCK IMPROVES FIBROSIS BY RESTORATION OF TGF-&BETA
In general, using these compounds is expected to be a new pathway to developing drugs for IS by suppressing ferroptosis
Frequently Asked Research Questions
Overlaid extracted ion chromatograms of all six peptides can be found in Figure 4A, Found diagnostic fragment ions can be found in Table 4
CrossRef Performance of APRI and FIB-4 Scores Compared to FibroScan: A Cross-Sectional Study in a Black Sub-Saharan African Population Jean-Bonny Nsumbu, Jean-Robert Makulo, Trsor Mutombo Tshiswaka, Christian Kisoka Lusunsi, Charles Nlombi Mbendi Hepatic Medicine: Evidence and Research .2025
